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Abstract
The hormone leptin is secreted from white adipocytes, and serum levels of leptin correlate with adipose tissue mass. Leptin was first 
described as acting on the satiety centre in the hypothalamus through specific receptors (ob-R) to restrict food intake and enhance energy 
expenditure. 
Leptin plays a crucial role in the maintenance of body weight and glucose homeostasis hrough central and peripheral pathways, in-
cluding regulation of insulin secretion by pancreatic b cells. Leptin may also directly affect the metabolism and function of peripheral 
tissues. Leptin has been implicated in causing peripheral insulin resistance by attenuating insulin action, and perhaps insulin signalling, 
in various insulin-responsive cell types. 
Research has demonstrated a significant relationship between leptin and insulin, but the mechanisms underlying the changes of leptin 
induced by insulin, and vice versa, remain to be studied in more detail.
Recent data provides convincing evidence that leptin has beneficial effects on glucose homeostasis in mouse models of insulin-deficient 
type 1 diabetes mellitus.
Our study suggests that leptin could be used as an adjunct of insulin therapy in insulin-deficient diabetes, thereby providing an insight 
into the therapeutic properties of leptin as an anti-diabetic agent. Safety evaluation should include a careful assessment of the effects of this 
combination therapy on the counterregulatory response to hypoglycaemia. The role of leptin in alpha-cell function has not been studied 
in detail. Extensive studies will be needed to determine the long-term safety and efficacy of this therapy. 
(Pol J Endocrinol 2011; 62 (3): 252–261)
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Streszczenie
Leptyna jest hormonem wydzielanym przez adipocyty, jej stężenie w surowicy koreluje z masą tkanki tłuszczowej. Pierwsze opisano 
działanie leptyny na ośrodek sytości w podwzgórzu poprzez jej specyficzne receptory (ob-R) dla hamowania przyjmowania pożywienia 
i zwiększania wydatkowania energii. Leptyna odgrywa zasadniczą rolę w utrzymaniu masy ciała i homeostazy glukozy. Odbywa się to na 
drodze jej działania ośrodkowego i obwodowego, włączając regulacje sekrecji insuliny przez komórki b. Leptyna także może bezpośrednio 
wpływać na metabolizm i funkcję tkanek obwodowych. Może być także włączona w powodowanie obwodowej oporności na działanie in-
suliny poprzez osłabianie działania insuliny i prawdopodobnie wrażliwości na jej działanie w różnych insulinowrażliwych typach komórek. 
Wiele danych przedstawia znamienne relacje pomiędzy leptyna i insuliną, lecz dla wyjaśnienia mechanizmów wpływu leptyny na insulinę 
i odwrotnie konieczne są dalsze badania. 
Ostatnie dane dobitnie wskazują, że leptyna wywiera korzystne działanie na homeostazę glukozy w badaniach u myszy z deficytem 
insuliny (cukrzyca typu 1). 
To sugeruje, że leptyna może być użyta jako lek wspomagający w terapii cukrzycy z niedoborem insuliny, tym samym rozważana do 
zastosowania w terapii jako lek przeciwcukrzycowy. 
Konieczna jest ocena bezpieczeństwa stosowania takiej terapii na odpowiedź mechanizmów kontrregulacyjnych na hipoglikemię. Dotych-
czas ostatecznie nie wyjaśniono wpływu leptyny na funkcje komórek a. Konieczne są szczegółowe badania efektywności i długotrwałego 
bezpieczeństwa takiej terapii. (Endokrynol Pol 2011; 62 (3): 258–261)
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The results of experimental and clinical research by 
American scientists into the use of leptin in type 1 dia-
betes mellitus treatment have recently been published 
[1–4]. It would be useful to remind ourselves of the role 
of leptin in the maintenance of energy homeostasis in 
the body, as well as look back at previous assessments 
of its therapeutic use [5–9].
Leptin is one of the adipokines, and its synthesis is 
controlled by the “ob” gene located on the 7q31.3 chro-
mosome [10]. Leptin plays a key role in body energy 
balance regulation. Its receptors ‘ob-R’ sites placement 
determines both central and peripheral leptin action 
[11–13]. Receptors are located mainly in the hypothalamus, 
but shorter isoforms are found peripherally in multiple organ 
tissues such as the liver, intestines, muscles, adipose tissue, 
pancreatic b cells, heart, lungs and kidneys.
Leptin, discovered only a dozen or so years ago, has 
provoked great interest from the very start, as witnessed by 
numerous publications looking at the mechanisms of its ac-
tion and its influence on metabolic processes [14–17]. Leptin 
is secreted in pulses in daily rhythm, its secretion peak taking 
place at night, when its concentration is 30–100% higher than 
in the morning.
Leptin levels reflect not only the amount of accu-
mulated fat, but also an individual’s energy balance. 
Changes in leptin secretion have a significant influence 
on many metabolic and hormonal human body pro-
cesses [14, 18, 19].
Insulin plays an important role in leptin secretion 
regulation. Indeed animal experimental studies suggest 
a direct insulin influence on leptin secretion.
After release from adipocytes, leptin is transported 
though the blood-brain barrier to the central nervous 
system, where via other peptides and the sympathetic 
system it causes hunger inhibition and a sensation of sati-
ety. Leptin controls the body energy balance by inhibiting 
the secretion of neurotransmitters, including neuropep-
tide Y (NPY), which is the strongest hunger stimulator 
included in orexigenic compounds. Stimulation of MSH 
(melanocyte-stimulating hormone) release, caused by 
leptin, also inhibits hunger. Another leptin-dependent 
anorectic factor is CART (cocaine amphetamine-regulated 
transcript), a neuropeptide found in the hypothala-
mus. Glucagon-like peptide 1 (GLP-1) also probably takes 
place in the metabolic action of leptin.
Besides central action, many peripheral leptin effects 
have been described, including its influence on insulin 
secretion and action, the metabolism of adipocytes and 
skeletal muscles. Leptin is considered to be one of the 
peripheral glucose homeostasis regulators. It is also 
considered a metabolic signal regulating reproductive 
functions, haematopoesis, etc.
Leptin secretion differs in different stages of life 
[17, 20–23].
An insufficiency of leptin action may be caused by 
secretion disorders, disturbances of its transport from 
adipose tissue to the hypothalamus, or incorrect ob-R 
hypothalamic receptors function.
Role of leptin in maintaining glucose 
homeostasis
Leptin may act through receptors located in the CNS, 
but it may also have a direct action on different tis-
sues. There is a direct relationship between leptin 
and insulin. The presence of leptin receptors in b cells 
indicates leptin’s involvement in endocrine pancreas 
function [24, 25].
It is assumed that insulin increases leptin production 
by adipose tissue, whereas leptin inhibits insulin secre-
tion and insulin gene expression. The suppressive action 
of leptin on insulin production is regulated both by the 
autonomous nervous system and directly by influence 
on leptin receptors in b cells. It can inhibit both basal 
and glucose-stimulated insulin secretion.
The mechanisms of the actions are varied: insulin se-
cretion inhibition may be caused by leptin influence on 
ATP-dependent potassium channels. It is also believed 
that leptin antagonises cAMP signalling, and diminishes 
increases of cellular cAMP levels in response to b cells 
stimulation, for example by GLP-1. 
It appears that leptin may antagonise insulin secretion 
from b cells both through cAMP-dependent protein kinase 
A (PKA), and protein kinase C (PKC) [26].
Leptin may play a role in preventing insulin hyper-
secretion. The mechanism of this regulation is yet to be 
fully explained [24].
It is clear that leptin’s role in metabolic processes is 
not limited only to hunger regulation. It takes part in 
multiple processes, for example accelerating glucose 
utilisation and taking part in fat metabolism [15]. It has 
been proved that leptin or leptin receptors deficiency, 
both in ob/ob mice and in humans, leads not only to 
obesity development, but also increases insulin resist-
ance and glucose intolerance, which are risk factors for 
diabetes development [24, 27, 28]. Experimental studies 
have shown that prolonged intravenous leptin infu-
sion causes an increase of glucose use by an increase 
of tissues’ insulin sensitivity. Moreover, an increase of 
insulin inhibiting influence on liver glucose production 
has been found [2, 29].
There are disagreements concerning leptin’s influ-
ence on insulin secretion, and the results of studies into 
its influence on insulin resistance are also not clearcut [2, 
30, 31]. It seems that part of these differences might be 
caused by the fact that experimental studies are partly 
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carried out in vitro on isolated cells, which excludes 
central leptin action. This also partly explains the dif-
ferences between the results of experimental studies 
and clinical observations in humans.
An important role in maintaining glucose homeos-
tasis is also played by leptin’s influence on pancreas 
a cells. Experimental studies have found leptin to have 
an inhibitory action on these cells [19].
Leptin in diabetes mellitus and the outlook 
for its future use in therapy
Leptin secretion and leptin receptors disturbances have 
been found in diabetes patients [17, 32]. 
Leptin induces liver gluconeogenesis, inhibits 
insulin release from pancreatic b cells, and probably 
also causes break-down of insulin receptors. Finding 
a link between the presence of active leptin receptors 
and an increased number of b cells would appear to 
be important for the prospects of diabetes treatment 
[3, 4, 25, 27, 33]. 
There are many disagreements concerning leptin’s 
concentration in patients with diabetes. This is because 
the leptin level depends on many factors.
An increased leptin level compared to that found 
in healthy pregnant women has been found in 
women with gestational diabetes mellitus (GDM) or 
glucose intolerance freshly diagnosed during preg-
nancy [23]. An increased leptin cencentration has 
also been found in newborn babies of mothers with 
type 1 diabetes [34].
Studies performed in children and adolescents with 
type 1 diabetes mellitus indicate marked differences 
depending on the subjects’ age, diabetes duration time 
and degree of metabolic control [17]. In adolescents 
with type 1 diabetes in the pubertal period, leptin con-
centration was higher than in a control group, while in 
girls there was a correlation with adipose tissue mass 
increase, although not all authors have confirmed these 
observations [21, 31]. As Kratzsch et al. has demonstra-
ted [35], dramatic changes take place at fresh diabetes 
onset during metabolic decompensation: the number of 
soluble leptin receptors (sOB-R) increases, while leptin 
concentration drops. The pathophysiologic mechanisms 
of these changes are not yet fully understood, but they 
are probably connected to leptin resistance.
A marked decrease of leptin concentration has been 
found in patients during diabetes ketoacidosis (DKA) 
[36, 37]. Initial leptin concentrations were significantly 
lower compared to a control group. Introducing insulin 
treatment increased the leptin level. The main cause 
of leptin decrease during DKA is probably insulin de-
ficiency. Introducing insulin therapy increases leptin 
concentration.
Serum leptin concentration in type 2 diabetes pa-
tients varies, and seems to have a connection to dura-
tion of diabetes. Low leptin concentrations have been 
found in obese patients with poorly controlled type 2 
diabetes who show insulin deficiency. This is similar 
to what is found in DKA during type 1 diabetes. It 
confirms the assumption that one of the mechanisms 
leading to decreased leptin concentration may be 
insulin deficiency.
Concerning leptin concentration changes in patients 
with diabetes, it has been suggested that leptin could be 
used as an anti-diabetic drug, or as an addition to insulin 
therapy in insulin-dependent diabetes [1, 3, 9, 38, 39].
Studies of animals without obesity, and with ex-
perimentally induced diabetes, have shown that the 
destruction of b cells is accompanied by a decrease of 
leptin mRNA expression and serum leptin concentra-
tion [40].
Treating rats with recombinant leptin was found to 
restore euglycemia and normalise peripheral insulin 
sensitivity, which was found using a hyperinsulinemic 
euglycemic clamp [41].
An interesting study by Kojima et al. showed that 
leptin gene therapy regulates glucose concentration and 
energy homeostasis in diabetic rats [42]. The beneficial 
influence of leptin on glucose and lipids control in 
diabetic rats has also been demonstrated by Kusakabe 
et al. [43].
Recently, an extensive description of leptin’s role in 
glucose homeostasis maintenance in both laboratory 
animals and humans has been put forward by Kraus et 
al. [3]. The mechanism of its function varies according 
to endogenous leptin level. The authors suggest further 
clinical studies are needed for a final assessment of its 
therapeutic safety.
Despite multiple reports published in recent years, 
many aspects of leptin secretion, action and mechanisms 
of its influence on carbohydrates and fats metabolism 
still await explanation. Data, as mentioned before, seems 
to indicate an adipo-insular axis. Both experimental 
results and clinical observations indicate a  relationship 
between leptin and insulin secretion.
These observations may help in guiding therapy [2, 
44]. It has been suggested that leptin might be used as 
an anti-diabetic drug or as an addition to insulin therapy 
in insulin-dependent diabetes patients [1, 3, 9, 38, 39]. 
The study by Yildiz et al. showed that leptin might 
be used for diabetes or glucose intolerance treatment 
in non-obese patients with decreased leptin level [39].
In some cases, the use of recombined leptin is the 
only effective means of treatment of the severe meta-
bolic disorders that accompany lipoatrophy. Leptin’s 
usefulness in patients with type 1 diabetes mellitus with 
generalised lipodystrophy has also been described [45].
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At the present,  leptin is known to be involved in mul-
tiple metabolic processes and in glucose metabolism. 
There have been many attempts to use  these actions 
in diabetes treatment of obese type 2 patients, as well 
as in type 1 diabetes. 
The results of experimental studies are encouraging. 
However, assessing the use of such therapy n humans 
demands further clinical studies. It is especially impor-
tant to assess the risk of hypoglycaemia, considering 
leptin’s suppressive effect on a cells.
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